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Abstract
Aims Sufficient myocardial recovery with the subsequent explantation of a left ventricular assist device (LVAD) occurs in ap-
proximately 1–2% of the cases. However, follow-up data about this condition are scarcely available in the literature. This study
aimed to report the long-term outcomes and clinical management following LVAD explantation.
Methods and results An analysis of the European Registry for Patients with Mechanical Circulatory Support was performed
to identify all adult patients with myocardial recovery and successful explantation. Pre-implant characteristics were retrieved
and compared with the non-recovery patients. The follow-up data after explantation were collected via a questionnaire. A
Kaplan–Meier analysis for freedom of the composite endpoint of death, heart transplantation, LVAD reimplantion, or heart
failure (HF) relapse was conducted. A total of 45 (1.4%) cases with myocardial recovery resulting in successful LVAD explanta-
tion were identified. Compared with those who did not experience myocardial recovery, the explanted patients were younger
(44 vs. 56 years, P < 0.001), had a shorter duration of cardiac disease (P < 0.001), and were less likely to have ischaemic car-
diomyopathy (9% vs. 41.8%, P < 0.001). Follow-up after explantation could be acquired in 28 (62%) cases. The median age at
LVAD implantation was 43 years (inter-quartile range: 29–52), and 23 (82%) were male. Baseline left ventricular ejection frac-
tion was 18% (inter-quartile range: 10–20%), and 60.7% of the patients had Interagency Registry for Mechanically Assisted Cir-
culatory Support Profile 1 or 2. Aetiologies of HF were dilated cardiomyopathy in 36%, myocarditis in 32%, and ischaemic in
14% of the patients, and 18% had miscellaneous aetiologies. The devices implanted were HeartMate II in 14 (50%), HVAD
in 11 (39%), HeartMate 3 in 2 (7%), and 1 unknown with a median duration of support of 410 days (range: 59–1286). The me-
dian follow-up after explantation was 26 months (range 0.3–73 months), and 82% of the patients were in New York Heart As-
sociation Class I or II. Beta-blockers were prescribed to 85%, angiotensin-converting enzyme inhibitors to 71%, and loop
diuretics to 50% of the patients, respectively. Freedom from the composite endpoint was 100% after 30 days and 88% after
2 years.
Conclusions The survival after LVAD explantation is excellent without the need for heart transplantation or LVAD reimplan-
tation. Only a minority of the patients suffer from a relapse of significant HF.
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Introduction
Continuous flow left ventricular assist devices (cf-LVADs) have
become an important modality in the treatment of end-stage
heart failure (HF) as a bridge to transplantation (BTT), bridge
to candidacy, or as destination therapy. This has led to a sig-
nificant improvement of the quality of life and overall survival
of patients once all other therapeutic options have been
exhausted.1
A small percentage of these patients experience signifi-
cant myocardial recovery under LVAD support and can
therefore undergo LVAD explantation, defined as actual
bridge to recovery (BTR).1 The eighth Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS)
annual report and the second European Registry for
Patients with Mechanical Circulatory Support (EUROMACS)
report, reported that 1–2% of the patients implanted with
cf-LVADs recovered, allowing successful LVAD explanta-
tion.1,2 Similarly, in a pooled HeartMate II cohort with
1108 patients enrolled, the rate of myocardial recovery
was 1.8%.3
Several case series and small cohort studies report patients
having sufficient recovery of left ventricle (LV) function that
allowed LVAD explantation. These studies show higher rates
of myocardial recovery after LVAD explantation and survival
ranging from 78.3% to 100%, with varying rates of HF recur-
rence.4–8
These studies report encouraging survival outcomes;
however, much remains unknown concerning adverse
events (AEs) and HF management after explantation and
most studies are based on single-centre experiences.
Little is known about long-term outcomes and AEs, such
as ventricular tachycardia or thromboembolic complications,
given the fact that the inflow cannula is not (always)
extracted and data about its management are usually
lacking. Furthermore, the follow-up of these patients is
limited, and details on specific medication are lacking and
not consistent because of a small number of patients.
There is no evidence-based knowledge regarding the long-
term treatment of these patients in case of recurrence
of HF or other complications. Such inconsistencies prompt
a need for a complete long-term follow-up in these pa-
tients, with a special emphasis on chronic medication,
AEs, and longer-term survival after successful LVAD
explantation.
Objectives
The aim of the study is to evaluate long-term outcomes and
patient management after a successful LVAD termination
due to the recovery, including survival, complications, relapse
of HF, and specific medical treatments.
Methods
Study design
A retrospective study was conducted in all patients in whom
an LVAD was successfully explanted after myocardial recov-
ery as registered in the EUROMACS.2,9 Inclusion criteria were
successful explantation of a cf-LVAD (as a stand-alone VAD
system, not right VAD) as captured in the follow-up of
EUROMACS. Exclusion criteria included an explantation due
to any other reason than myocardial recovery (e.g. infection
and device malfunction) or patients aged <18 years.
Data collection
From January 2011 until March 2018, a total of 45 patients
in the EUROMACS registry were identified as being success-
fully explanted after myocardial recovery, from now on
named recovery patients. Baseline characteristics before
LVAD implantation including age, sex, aetiology of HF,
pre-operative condition and co-morbidities, electrocardio-
gram, echocardiogram, and blood chemistry values were
collected for adult patients in EUROMACS. Furthermore,
perioperative data on device strategy, device type, concom-
itant surgical procedures, and cardiopulmonary bypass
(CPB) time, time in operating room, intensive care unit,
and hospital stay were retrieved. Finally, time on LVAD
and type and number of AEs and hospitalizations were col-
lected from the follow-up.
Subsequently, a detailed questionnaire was sent to in-
volved centres to attain the follow-up of these patients after
LVAD explantation. These data are currently not captured in
the EUROMACS registry. Because data entry into EUROMACS
is anonymized for external reviewers, the executive director
(T. M. M. H. d. B.) approached the centres asking to provide
the follow-up of these patients. Data collected included the
primary outcome: survival, heart transplantation (HTx), reim-
plantation of LVAD, and data on re-hospitalizations due to HF.
Secondary outcomes consisted of the following parameters:
presence of the inflow cannula, the occurrence of cerebro-
vascular accidents, New York Heart Association (NYHA) class
at last follow-up, oral anticoagulation, and HF medication. Fi-
nally, data of electrocardiogram, echocardiography, and
blood chemistry values were requested.
Statistical analysis
Continuous parameters are expressed as mean and confi-
dence interval or median and range or inter-quartile range.
Categorical parameters are expressed as number and per-
centage. For categorical parameters, χ2 test and Fisher’s ex-
act test were applied as appropriate. For continuous
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parameters, Student’s t-test and Wilcoxon rank-sum test
were used. A comparison of baseline characteristics was
performed to assess differences in patients with VAD ex-
plantation and without VAD explantation. Furthermore,
baseline characteristics of patients whose LVAD was
explanted with and without follow-up were compared to as-
sess a potential reporting bias. Finally, a Kaplan–Meier
curve was constructed to evaluate freedom of the compos-
ite endpoint of death, HTx, LVAD reimplantation, or relapse
of HF ≥ NYHA III after LVAD explantation. Statistical analysis
was performed using SPSS, Version 25.0 for Windows (IBM
Inc., Armonk, NY, USA).
Results
Baseline characteristics
A total of 45 patients in whom the LVAD was explanted be-
cause of myocardial recovery were identified in the
EUROMACS registry, representing 1.4% of the patients regis-
tered at the time. A complete follow-up of 28 (62.2%) re-
covery patients after explantation was obtained. In these
patients, median age at implantation was 43 years (range
29–52) and 23 patients (82.1%) were male (Table 1A). Pre-
dominant aetiologies of HF were myocarditis in nine
(32.1%) patients and dilated cardiomyopathy in 10 (35.7%)
patients. Most patients had a short history of cardiac dis-
ease, with 14 (50%) patients having had their first cardiac
diagnosis less than 1 month prior to the LVAD implantation
and 20 (71.4%) within 1 year prior to the implantation. Pa-
tients were almost evenly distributed over INTERMACS Pa-
tient Profiles I to III, only three patients had INTERMACS
Patient Profile IV–V. Median LVEF was 18% (inter-quartile
range: 10–20%), whereas five patients exhibited greater
than or equal to moderate mitral regurgitation. At the time
of implant, 23 (82.1%) patients had inotropic support and
14 patients (50%) experienced any form of mechanical circu-
latory support by either extracorporeal life support or an
intra-aortic balloon pump. There were, apart from mitral re-
gurgitation, no significant differences between patients with
or without an obtained follow-up after LVAD explantation
(Table 1A).
A comparison between patients whose LVAD was
explanted and patients with another outcome (ongoing,
HTx or death) reveals that recovery patients were signifi-
cantly younger (45 vs. 53.5 years; P < 0.001), had a shorter
duration of cardiac disease (P < 0.001) and less implant-
able cardioverter-defibrillators implanted (8.9% vs. 61.4%;
P < 0.001), and were more often in INTERMACS Patient
Profile 1 (P = 0.01; Table 1B). Furthermore, the predomi-
nant aetiologies of HF were myocarditis and dilated cardio-
myopathy for recovery patients, while ischaemic
cardiomyopathy was the main cause of HF in the non-
recovery group.
Perioperative characteristics
The indication designation was BTT in 22 (78.5%), destination
therapy in 2 (7.1%), and rescue therapy in 4 (14.3%) (Table 3).
Implanted devices included the HeartMate II (n = 14) (Abbott,
Lake Bluff, IL, USA), HeartWare HVAD (n = 11) (Medtronic,
Minneapolis, MN, USA), HeartMate 3 (n = 2) (Abbott, Lake
Bluff, IL, USA), and one unknown device. Concomitant cardiac
surgery was performed in five patients: three patent foramen
ovale repairs, one tricuspid valve repair, and one aortic valve
replacement. Two patients received a temporary right VAD.
Median time in the operating room was 208 min (range:
130–683), with a median CPB time of 75 min (95–147).
Post-operative intensive care unit stay ranged from 4 to 147
days with a median of 17 days and a median hospital stay
of 30 days (17–165). Patients with a follow-up after LVAD ex-
plantation had significantly different device strategies (P <
0.001) (less BTR and more BTT patients) and a shorter dura-
tion of CPB (P = 0.034) compared with patients without a
follow-up.
Outcomes during ventricular assist device
support
The median support time of the patients was 410 days (59–
1286). Within this time frame, the following key AEs were
captured: major infection, major bleeding and device mal-
function, and haemolysis (Table 4). Eight (28.6%) patients
remained free of any AEs during LVAD support, while 10 pa-
tients (35.7%) encountered three or more AEs. Forty-eight
(73.8%) captured AEs required a hospitalization. There were
no significant differences to the patients with missing
follow-up after explantation.
Outcomes after left ventricular assist device
explantation
Median follow-up time after LVAD explantation is 26
months (0.3–73). Freedom from death, LVAD reimplanta-
tion, HTx, and relapse of HF ≥ NYHA III was 100% at 30
days and 88% at 24 months after explantation (Figure 1
and Table 5). Two patients encountered an HF relapse,
which is in part attributable to new onset of degenerative
mitral regurgitation in one patient. One patient required re-
implantation of an LVAD after 32 days. Finally, one patient
died 302 days after LVAD explantation due to sepsis. Until
48 months, this percentage remained unchanged (88%);
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Table 1 A: Baseline characteristics of all patients with left ventricular assist device explantation due to myocardial recovery with and with-
out follow-up after explantation
With follow-up (28) No follow-up (17) P-value
Age (years) 43 (29–52) 53 (41–65) 0.053
Male 23 (82.1) 13 (76.5) 0.711
BMI(kg/m2) 26.9 [25.1–28.6] 25.7 [23.2–28.2] 0.182
BSA(m2) 2.02 [1.92–2.12] 1.98 [1.87–2.10] 0.395
Aetiology 0.579
Myocarditis 9 (32.1) 3 (17.6)
Dilated cardiomyopathy 10 (35.7) 4 (23.5)
Ischaemic cardiomyopathy 4 (14.3) 5 (27.1)
Peripartum 1 (3.6) 1 (5.9)
Valvular heart disease 2 (7.1) 2 (11.8)
Hypertrophic cardiomyopathy 0 (0) 1 (5.9)
Toxic 1 (3.6) 0 (0)
Restrictive cardiomyopathy 0 (0) 0 (0)
Congenital heart disease 0 (0) 0 (0)
Other/unknown 1 (3.6) 1 (5.9)
Time since first cardiac diagnosis 0.453
<1 month 14 (50) 6 (35.3)
1 month–1 year 6 (21.4) 5 (29.4)
1 year or more 4 (14.3) 5 (29.4)
Unknown 4 (14.3) 1 (5.9)
Current ICD in place 2 (7.1) 2 (11.8) 1.000
INTERMACS profiles 0.918
INTERMACS 1 8 (28.6) 6 (35.3)
INTERMACS 2 9 (32.1) 6 (35.3)
INTERMACS 3 8 (28.6) 3 (17.6)
INTERMACS 4–5 3 (10.7) 2 (11.8)
INTERMACS 6–7 0 (0) 0 (0)
Echocardiography
LVEF (%) 18 (10–20) 15 (15–20) 0.612
LVEDD (mm) 68 (63–70) 66 (62–73) 0.771
Aortic regurgitation ≥ moderate 1 0 1.000
Mitral regurgitation ≥ moderate 4 9 0.038
ECG rhythm 0.389
Sinus 18 (64.3) 14 (82.4)
Atrial fibrillation/flutter 5 (17.9) 3 (17.6)
Paced 1 (3.6) 0 (0)
Other/unknown 4 (14.3) 0 (0)
Heart rate (b.p.m.) 97 (89–121) 98 (74–111) 0.455
Blood pressure (mmHg)
Systolic 105 (92–115) 106 (94–114) 0.919
Diastolic 61 (60–70) 67 (50–70) 0.942
Mean arterial pressure 74 (72–84) 78 (70–82) 0.965
Diabetes 2 (7.1) 0 (0) 0.519
Inotropic support
Intravenous inotropes 23 (82.1) 14 (82.4) 0.333
1–2 inotropes 18 (64.3) 8 (47.1)
≥3 inotropes 5 (17.9) 6 (35.3)
IABP 4 (14.3) 3 (17.6) 1.000
ECLS 10 (35.7) 7 (41.2) 0.715
Mechanical ventilation 8 (28.6) 6 (35.3) 0.637
Blood chemistry
Creatinine (μmol/L) 105 (79–114) 114 (91–141) 0.142
ALAT (U/L) 76 (39–177) 46 (34–520) 0.892
ASAT (U/L) 180 (42–592) 73 (27–184) 0.147
LDH (U/L) 469 (308–1189) 407 (338–992) 0.859
Total bilirubin (mg/dL) 1.5 (0.8–2.5) 1.5 (0.8–2.1) 0.525
Haemoglobin (g/dL) 11.8 (10.2–13.4) 10.9 (10.4–13.7) 0.971
White blood cell count (× 109/L) 10.6 (9.3–14.3) 10.7 (8.7–13.4) 0.819
Thrombocytes (× 109/L) 164 (75–241) 191 (104–266) 0.479
ALAT, alanine aminotransaminase; ASAT, aspartate transaminase; BMI, body mass index; BSA, body surface area; ECG, electrocardiogram;
ECLS, extracorporeal life support; IABP, intra-aortic balloon pump; ICD, implantable cardioverter-defibrillator; INTERMACS, Interagency
Registry for Mechanically Assisted Circulatory Support; LDH, lactate dehydrogenase; LVEDD, left ventricular end-diastolic diameter; LVEF,
left ventricular ejection fraction.
Values are median (inter-quartile range), mean [confidence interval], or n (%).
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Table 1 B: Baseline characteristics of all patients with and without left ventricular assist device explantation due to myocardial recovery
Explanted Not explanted P-value
Age (years) 44 (32–54) 56 (47–62) <0.001
Male 36 (80.0) 2568 (83.6) 0.542
BMI(kg/m2) 26.4 [25.0–27.8] 26.1 [26.0–26.3] 0.691
BSA(m2) 2.00 [1.93–2.08] 1.97 [1.96–1.98] 0.313
Aetiology <0.001
Myocarditis 12 (26.7) 125 (4.1)
Dilated cardiomyopathy 14 (31.1) 995 (32.4)
Ischaemic cardiomyopathy 9 (20) 1285 (41.8)
Peripartum 2 (4.4) 14 (0.5)
Valvular heart disease 4 (8.9) 45 (1.5)
Hypertrophic cardiomyopathy 1 (2.2) 30 (1.0)
Toxic 1 (2.2) 51 (1.7)
Restrictive cardiomyopathy 0 (0) 20 (0.7)
Congenital heart disease 0 (0) 28 (0.9)
Other/unknown 2 (4.4) 480 (15.6)
Time since first cardiac diagnosis <0.001
<1 month 20 (44.4) 302 (11.1)
1 month–1 year 11 (24.4) 356 (13.1)
1 year or more 9 (20) 1857 (68.4)
Unknown 5 (11.1) 198 (7.3)
Current ICD in place 1633 (61.4) 4 (8.9) <0.001
INTERMACS profiles 0.01
INTERMACS 1 14 (31.1) 412 (13.4)
INTERMACS 2 15 (33.3) 996 (32.4)
INTERMACS 3 11 (24.4) 781 (25.4)
INTERMACS 4–5 5 (11.1) 637 (21.6)
INTERMACS 6–7 0 (0.0) 123 (4.2)
Echocardiography
LVEF (%) 17 (15–19) 19 (19–19) 0.125
LVEDD (mm) 65.6 (62.2–69.0) 71.3 (70.1–72.6) 0.270
Aortic regurgitation greater than or equal to moderate 1 (3.4) 92 (3.8) 1.000
Mitral regurgitation greater than or equal to moderate 13 (38.2) 1221 (50.9) 0.141
ECG rhythm 0.005
Sinus 32 (71.1) 1359 (51.5)
Atrial fibrillation/flutter 8 (17.8) 424 (16.1)
Paced 1 (2.2) 663 (25.1)
Other/unknown 4 (8.9) 192 (7.3)
Heart rate (b.p.m.) 100 (92–107) 87 (86–87) <0.001
Blood pressure (mmHg)
Systolic 106 (100–112) 100 (100–102) 0.048
Diastolic 64 (59–69) 65 (64–65) 0.725
Mean arterial pressure 78 (73–83) 77 (76–77) 0.519
Diabetes 2 (4.4) 2105 (73.5) 0.001
Inotropic support
Intravenous inotropes 37 (82.2) 2495 (89) 0.547
1–2 inotropes 26 (57.8) 2149 (76.7)
≥3 inotropes 11 (24.4) 346 (12.3)
IABP 7 (15.9) 297 (11.3) 0.342
ECLS 17 (37.8) 303 (10.5) <0.001
Mechanical ventilation 14 (31.1) 406 (15.4) 0.004
Blood chemistry
Creatinine (μmol/L) 111 (83–123) 111 (85–150) 0.465
ALAT (U/L) 29 (54–177) 29 (18–70) 0.001
ASAT (U/L) 135 (31–410) 33 (23–74) <0.001
LDH (U/L) 434 (314–1173) 308 (238–452) <0.001
Total bilirubin (mg/dL) 1.78 (0.78–2.26) 1.29 (0.80–2.10) 0.591
Haemoglobin (g/dL) 11.9 (10.3–13.6) 11.8 (10.2–13.5) 0.844
White blood cell count (× 109/L) 10.7 (8.9–14.0) 8.4 (6.7–11.0) <0.001
Thrombocytes (× 109/L) 173 (80–247) 199 (150–250) 0.030
ALAT, alanine aminotransaminase; ASAT, aspartate transaminase; BMI, body mass index; BSA, body surface area; ECG, electrocardiogram;
ECLS, extracorporeal life support; IABP, intra-aortic balloon pump; ICD, implantable cardioverter-defibrillator; INTERMACS, Interagency
Registry for Mechanically Assisted Circulatory Support; LDH, lactate dehydrogenase; LVEDD, left ventricular end-diastolic diameter; LVEF,
left ventricular ejection fraction.
Values are median (inter-quartile range), mean [confidence interval], or n (%).
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however, follow-up was only available for six patients for
this duration of follow-up.
Median LVEF at last follow-up is 40% (15–60), with a me-
dian left ventricular end-diastolic and end-systolic diameter
of 54 mm (41–74) and 43 mm (27–63), respectively. Patient’s
HF symptoms are predominantly NYHA I and II (82.2%) with
three patients suffering significant HF symptoms (NYHA III).
All patients were on at least one type of HF medication: with
Table 2 Implantation and post-implantation characteristics for recovery patients
With follow-up (28) No follow-up (17) P-value
Device strategy <0.001
BTT 22 (78.5%) 7 (36.9%)
DT 2 (7.1%) 2 (10.5%)
Rescue therapy 4 (14.3%) 2 (10.5%)
Bridge to recovery 0 (0%) 8 (42.1%)
Device type 0.204
HeartMate II 14 (50%) 6 (31.6%)
HVAD 11 (39.3%) 9 (47.4%)
HeartMate 3 2 (7.1%) 0 (0%)
PVAD 0 (0%) 2 (10.5%)
Other/unknown 1 (3.6%) 2 (10.5%)
Concomitant cardiac procedures
PFO/ASD closure 3 (10.7%) 2 (10.5%)
Tricuspid repair 1 (3.6%) 4 (21.1%)
Tricuspid replacement 1 (5.3%)
Aortic repair 1 (5.3%)
Aortic valve replacement 1 (3.6%)
Mitral repair 1 (5.3%)
CABG 1 (5.3%)
Concomitant temporary RVAD implantation 2 (7.1%) 2 (10.5%) 1.000
Time in OR (min) 208 (130–683) 276 (95–375) 0.600
Cardiopulmonary bypass time (min) 75 (95–147) 124 (50–235) 0.034
ICU stay (days) 17 (4–147) 27 (2–66) 0.377
Hospital stay (days) 30 (17–165) 39 (14–144) 0.328
ASD, atrial septal defect; BTT, bridge to transplantation; CABG, coronary artery bypass grafting; DT, destination therapy; ICU, intensive
care unit; OR, operating room; PFO, patent foramen ovale; RVAD, right ventricular assist device.
Values are median (range) or n (%).
Table 3 Time on support and AEs during mechanical circulatory support for recovery patients
With follow-up (28) No follow-up (17) P-value
Time on support (days) 410 (59–1286) 231 (10–1425) 0.06
Type of AEs
Major infection 21 (32.3%) 4 (14.3%)
Major bleeding 8 (12.3%) 1 (3.6%)
Device malfunction 6 (9.2%) 5 (17.9%)
Haemolysis 4 (6.2%) 2 (7.1%)
Cardiac arrhythmia 3 (4.6%) 1 (3.6%)
Stroke 2 (3.1%) 3 (10.7%)
Renal dysfunction 2 (3.1%) 4 (14.3%)
Right heart failure 0 (0%) 1 (3.6%)
Other 19 (29.2%) 7 (25%)
Number of AEs per patient 0.889
0 8 (28.6%) 5 (29.4%)
1–2 10 (35.7%) 8 (47.1%)
3–4 7 (25.0%) 3 (17.6%)
≥5 3 (10.7%) 1 (5.9%)
Hospitalizations required for AE 48 (73.8%) 26 (92.9%)
Hospitalizations per patient 1.000
0 10 (35.7%) 6 (35.3%)
1–2 11 (39.3%) 7 (41.2%)
3–4 5 (17.9%) 3 (17.6%)
≥5 2 (7.1%) 1 (5.9%)
AE, adverse event.
Values are median (range) or n (%).
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beta-blockers in 24/28 (85.7%) and angiotensin-converting
enzyme inhibitors in 20/28 patients (71.4%) being used most
frequently.
The inflow cannula remained in situ after explantation in
three patients (11%). Of these patients, two were on both
warfarin and aspirin and one patient only used warfarin.
The inflow cannula was not in situ in the 25 other patients,
two of them used both warfarin and aspirin. Long-term
anticoagulation treatment was aspirin in 43% of the patients,
while in 39%, warfarin was used. Four patients were pre-
scribed with both aspirin and warfarin. In eight (29%) pa-
tients, no anti-platelet or anticoagulation therapy was used.
No cerebrovascular accident was reported in any patient.
Discussion
This study provides a multi-centre, mid- to long-term follow-
up of patients whose LVAD was explanted because of myo-
cardial recovery. The mid- to long-term outcomes appear to
be encouraging with 88% of the patients surviving without
HTx, LVAD reimplantation, or relapse of HF at 24 months of
follow-up. Furthermore, the majority of patients suffered
from mild HF-symptoms only (NYHA Class I–II). The number
of patients with sufficient myocardial recovery for LVAD ex-
plantation is comparable with other registries such as
INTERMACS, which reported a successful weaning rate of ap-
proximately 1% in the latest annual report.10,11
A comprehensive review of single-centre studies reporting
on myocardial recovery allowing LVAD explantation found
weaning rates ranging from 4.5% to 63% and thus contrasts
with lower recovery rates reported in the INTERMACS or
EUROMACS registries.12 Some of these studies have reported
higher rates of successful weaning. Interestingly, some
showed a successful explantation rate of 12 in 19 (63%)
patients supported by a HeartMate II.13 However, this popu-
lation was young (mean age 35.2 years) and patients with
ischaemic heart disease were excluded. Moreover, they re-
ceived aggressive pharmacotherapy with maximum HF medi-
cation combined with clenbuterol (β2-agonist).
These high rates of recovery may partly be explained be-
cause of the commitment of some centres resulting in spe-
cific clinical and scientific focus on the recovery. This might
result in advanced, aggressive strategies to identify potential
patients eligible for LVAD explantation and thus treating
those patients with targeted and strictly regulated HF medi-
cation. Furthermore, studies that included patients with
non-ischaemic heart disease as aetiology of HF and patients
with recent onset of HF tend to have higher rates of success-
ful myocardial recovery. These observations correspond well
with our study in which the majority of patients had their first
cardiac disease diagnosis less than 1 year ago and ischaemic
cardiomyopathy represented an uncommon aetiology of HF.
Indeed, the baseline characteristics that are significantly dif-
ferent in patients with LVAD explantation are very similar to
the variables used in the INTERMACS Cardiac Recovery Score
of Wever-Pinzon et al.11
In the literature, several case series and small cohort stud-
ies report on patients having recovery of left ventricle (LV)
function that allowed LVAD explantation. Studies such as
Dandel et al.4 report that LVAD (Novacor) explantation was
successful in 32 of 131 patients with idiopathic dilated cardio-
myopathy, with a 5 year survival of 78.3% and 31.1% HF re-
currence rate in 3 years, after being supported with an
LVAD for a mean duration of 4.6 months (SD ± 4.4). Birks
et al.5 reported that out of 15 patients with severe HF due
to non-ischaemic cardiomyopathy, 11 had LVAD explantation
after a mean of 320 days of LVAD support; 88.9% of the sur-
viving patients were free from HF at 4 years after explanta-
tion. Another study showed that survival after explantation
of HeartMate II was 83.3% after 3 year follow-up.13 A study
Figure 1 Freedom of death, left ventricular assist device reimplantation, heart transplantation (HTx), and significant heart failure (HF) relapse after left
ventricular assist device explantation.
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of 14 patients revealed that after a mean follow-up time of
3.6 years (±1.9) after explantation, no patient had died and
had a functional NYHA class of I.6 Frazier et al.7 achieved ex-
plantation in 27 patients out 657 patients supported by an
LVAD, with 25 of them surviving after a mean follow-up of
3.2 years (±2.6) all of them with NYHA Class I with medical
therapy. In comparison, we showed a similar excellent sur-
vival of 88% without HTx, LVAD reimplantation or significant
HF relapse in a European multi-centre registry, with the ma-
jority of patients only suffering from mild HF symptoms after
explantation. This highlights that, in carefully selected pa-
tients, excellent results can be achieved after LVAD explanta-
tion and are not restricted to one centre.
Pathophysiology and clinical implications of left
ventricular recovery
The pathophysiology of HF is complex and multifactorial. Sys-
tolic HF is accompanied by LV remodelling, which is charac-
terized by three categories of changes in the heart: myocyte
defects, myocardial defects, and abnormal LV geometry.14
In contrast, to achieve myocardial recovery, the heart has
to undergo cardiac reverse remodelling. Support by cf-LVADs
results in left ventricular pressure and volume unloading as
well as increased cardiac output15,16 and has shown to pro-
mote certain forms of reverse remodelling17: reduction of
cardiac myocyte hypertrophy,18,19 changes in gene expres-
sion,20,21 and normalization of β-adrenergic receptor and ino-
tropic responsiveness.22 Concerning restoration of the
extracellular matrix, conflicting studies exist, with some stud-
ies reporting an increase in total extracellular matrix colla-
gen,23,24 while others report a decrease.25 Finally, studies
have shown an improvement in cardiac myocyte contractility
after LVAD implantation.26,27 There are some excellent re-
views covering this topic in much more detail.14,28 On the
clinical side, the criteria used for the decision of LVAD explan-
tation differ between centres.8,13,29 Clinical parameters that
indicate LV remodelling and might indicate myocardial recov-
ery often include an increase in LVEF, decreases in end-
diastolic left ventricular diameter, (partial) reversal of func-
tional mitral regurgitation, normalization of cardiac filling
pressures, and cardiac sinus rhythm with a normal heart rate.
Unfortunately, studies linking pathophysiological findings
with these clinical outcomes are scarce.
Future perspectives
A combination of clinical and biological findings for patients
undergoing LVAD implantation is currently lacking robust
data with both studies conducted separately of each other.
Preferably, one would collect histological/biological data
and clinical data before LVAD implantation, during LVAD sup-
port, and after explantation (if applicable). This holistic ap-
proach would provide much needed insight in the changes
that are induced by VAD therapy and would enable us to link
and understand pathophysiological changes to clinical
changes and vice versa.
Finally, because the number of patients that have suffi-
cient myocardial recovery to enable LVAD explantation is lim-
ited, it is critical that researchers and clinicians cooperate in
large registries such as EUROMACS and INTERMACS, by
adding data fields for centres willing to capture data on the
follow-up of these patients. As a consequence, the
EUROMACS board set out the goal that follow-up of after ex-
plantation of VAD devices due to recovery should also be cap-
tured in the near future.
Table 4 Long-term outcome post-LVAD explant for recovery
patients
Follow-up time (months) 26 (0.3–73)
Primary outcome
Ongoing after explant 26 (92.8%)
HF recurrence 3 (10.7%)
LVAD reimplantation 1 (3.6%)
Death 1 (3.6%)
BMI(kg/m2) 27.6 [25.4–29.7]
Blood pressure (mmHg)
Systolic 113 (88–160)
Diastolic 77 (51–98)
Mean arterial pressure 90 (68–113)
Echocardiography data
LVEF (%) 40 (15–60)
LVEDD (mm) 54 (41–74)
LVESD (mm) 43 (27–63)
MR grade ≥3 2
ECG
Heart rate (b.p.m.) 73 (48–105)
Rhythm
Sinus 21 (75%)
Atrial fibrillation/flutter 3 (10.7%)
Other 4 (14.3%)
QRS width (ms) 98 (74–188)
QTc duration (ms) 435 (374–593)
Blood chemistry
Creatinine (μmol/L) 97 (62–248)
Bilirubin (mg/dL) 0.6 (0.3–2.8)
Functional status at last follow-up
NYHA Class I 7 (25%)
NYHA Class II 16 (57.2%)
NYHA Class III 3 (10.7%)
Unknown 2 (7.1%)
HF medication
Beta-blockers 24 (85.7%)
ACE inhibitors 20 (71.4%)
Loop diuretics 14 (50%)
Inflow cannula in situ 3 (10.7%)
Anticoagulation/anti-platelet therapy 20 (71.4%)
Acetylsalicylic acid 12 (42.9%)
Vitamin K antagonist 11 (39.3%)
Both 4 (14.3%)
None 8 (29%)
Number of patients with CVA 0 (0%)
ACE, angiotensin-converting enzyme; BMI, body mass index; CVA,
cerebrovascular accident; ECG, electrocardiogram; HF, heart fail-
ure; LVAD, left ventricular assist device; LVEDD, left ventricular
end-diastolic diameter; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic diameter; MR, mitral regurgita-
tion; NYHA, New York Heart Association.
Values are median (range), mean [standard deviation], or n (%).
8 C.F.J. Antonides et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12629
Limitations
This study has certain limitations that should be considered
while interpreting the results. Data were gathered retrospec-
tively, and the number of data fields captured is limited. Fur-
thermore, it is possible that not all patients whose LVAD was
explanted because of recovery were captured in the
EUROMACS registry. It is also possible that the follow-up of
patients who actually have been explanted because of recov-
ery has not been registered yet. This might result in a relative
underestimation of the number of patients with myocardial
recovery; however, the EUROMACS registry regularly checks
and audits participating centres for data quality and comple-
tion. Finally, we only received follow-up data on 62% of those
patients weaned from LVAD support, which may constitute a
potential selection bias resulting in favourable outcomes.
However, the baseline characteristics and follow-up during
LVAD support of patients with and without follow-up were,
apart from one variable, not significantly different (Table 1A).
Conclusions
To our knowledge, this is one of the first multi-centre studies
to review midterm to long-term follow-up after LVAD explan-
tation due to myocardial recovery. Although LVAD explanta-
tion remains rare, outcomes after explantation are excellent
with a majority of patients ongoing without HTx or LVAD re-
implantation while having limited HF symptoms only. Large,
prospective registries and/or studies are required to generate
pertinent data in order to better understand this challenging
population.
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